Research library

B

grade

A three-month-old infant received an accidental double dose of vosoritide but showed no adverse reactions, indicating potential variability in response among infants.

0.24 mg vosoritide administered, equivalent to 53 μg/kg.

summary

A

grade

Vosoritide significantly increased growth velocity in children with hypochondroplasia compared to placebo over one year, but further studies are needed to confirm these findings.

LSM difference of 2.33 cm/year between vosoritide and placebo; 95% CI, 1.85-2.82 cm/year; two-sided P<0.0001.

summary

A

grade

Vosoritide treatment resulted in a significant increase in growth velocity in children with hypochondroplasia compared to placebo over one year.

LSM difference of 2.33 cm/year between vosoritide and placebo, 95% CI 1.85-2.82 cm/year, two-sided P<0.0001.

summary

B

grade

Vosoritide may improve daily activities and independence in children with genetic short stature, according to qualitative reports from children and caregivers.

74% of caregivers and 100% of children reported changes in daily activities.

summary

D

grade

Clinical pharmacology's integration of diverse data sources supports rare-disease drug development by informing key regulatory decisions.

summary

A

grade

Vosoritide therapy may be linked to an increased risk of slipped capital femoral epiphysis in some children with genetic short stature, particularly those with Turner syndrome and Aggrecan mutations.

2/12 participants with ACAN mutations developed SCFE.

summary

B

grade

Vosoritide treatment in children with achondroplasia showed significant increases in height Z-scores and high caregiver satisfaction in a real-world setting.

Height Z-scores increased from 0.33 to 1.58 between 6 to 36 months, p<0.001 to p<0.05.

summary

D

grade

Vosoritide has shown potential to improve growth velocity in children with achondroplasia, but uncertainties remain about long-term outcomes and safety.

Not reported in abstract.

summary

B

grade

Achondroplasia requires lifelong, multidisciplinary management to address its complex healthcare and psychosocial needs, with vosoritide being one of several components in care.

Not reported in abstract.

summary

C

grade

BMN 111 showed significant long bone growth in a Crouzon syndrome mouse model, but its effects on skull dimensions were limited.

Not reported in abstract.

summary

C

grade

The study suggests that combining a phosphatase inhibitor with an NPR2 agonist may enhance bone growth in a mouse model of achondroplasia, but further research is needed to confirm these effects in humans.

Not reported in abstract.

summary

C

grade

Vosoritide treatment in mice increased osteoblast levels and altered bone-related mRNA expression, but did not enhance mineral apposition rates.

Sclerostin mRNA was elevated 400-fold.

summary

A

grade

Vosoritide significantly increased growth velocity in children with RASopathies, ACAN, and NPR2 deficiency, but long-term safety concerns need to be addressed.

AGV increased from 4.53 ± 1.61 cm/year to 8.09 ± 1.58 cm/year with treatment (P < .0001).

summary

D

grade

Real-world evidence studies are becoming more common in postmarket evaluations but are still rarely used for premarket approvals, with many studies not completed on time.

43 (10.8%) had at least one real-world evidence study supporting premarket determinations.

summary

C

grade

Combining the phosphatase inhibitor LB-100 with the NPR2 agonist BMN-111 resulted in a ∼25% increase in femur growth in a mouse model of achondroplasia, suggesting a potential avenue for enhancing bone growth.

∼25% increase in femur growth vs BMN-111 alone.

summary

D

grade

Vosoritide shows promise in improving growth metrics in children with achondroplasia, particularly at higher doses, but further research is needed to fully understand its effects and safety profile.

Higher vosoritide doses (15 µg/kg or 15–30 µg/kg) showed significantly greater improvements in height z-scores compared to lower doses (2.5 µg/kg or 7.5 µg/kg) or placebo.

summary

C

grade

This study identifies a new interaction between NOC2L and LZTR1 that may affect p53 signaling in Noonan syndrome, suggesting a complex pathway that warrants further investigation.

Not reported in abstract.

summary

B

grade

Vosoritide treatment showed significant improvements in height z-scores and annual growth velocity in children with achondroplasia, but the clinical relevance of these findings should be interpreted cautiously.

Median annual growth velocity was 5.89 cm/year.

summary

B

grade

The QOLA questionnaire shows promise in assessing the quality of life for parents of children with achondroplasia, but further validation is necessary.

α = 0.798 for the total scale.

summary

B

grade

Patients who underwent humeral lengthening reported high satisfaction, while many untreated adults expressed regret about not having the procedure.

80% satisfaction reported by patients who underwent humeral lengthening.

summary

D

grade

This review highlights the need for ongoing research into genetic bone diseases and mentions vosoritide as a treatment option for achondroplasia, but further studies are needed to confirm its efficacy.

Not reported in abstract.

summary

B

grade

Early administration of vosoritide in infants with achondroplasia was tolerated, but it did not prevent complications like foramen magnum stenosis.

Not reported in abstract.

summary

A

grade

Vosoritide may not worsen complications in children with achondroplasia and might reduce their frequency, but further research is needed to confirm these findings.

Foramen magnum decompression frequency was 3.0% overall.

summary

A

grade

CNP analogs like vosoritide show statistically significant but modest improvements in growth for children with achondroplasia, alongside some safety concerns regarding specific adverse events.

1.36 cm/year increase in annualized growth velocity, 95% CI: 1.05-1.68, P < .00001.

summary

B

grade

Vosoritide increased height velocity and height SDS in children with achondroplasia over 24 months, but responses varied significantly among individuals.

Height velocity increased significantly at 24 months (+1.91 SDS) compared with baseline (p < 0.001).

summary